Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings: A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings : A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. / Aimo, Alberto; Vergaro, Giuseppe; González, Arantxa; Barison, Andrea; Lupón, Josep; Delgado, Victoria; Richards, A Mark; de Boer, Rudolf A; Thum, Thomas; Arfsten, Henrike; Hülsmann, Martin; Falcao-Pires, Inês; Díez, Javier; Foo, Roger S. Y.; Chan, Mark Yan Yee; Anene-Nzelu, Chukwuemeka G.; Abdelhamid, Magdy; Adamopoulos, Stamatis; Anker, Stefan D; Belenkov, Yuri; Ben Gal, Tuvia; Cohen-Solal, Alain; Böhm, Michael; Chioncel, Ovidiu; Jankowska, Ewa A.; Gustafsson, Finn; Hill, Loreena; Jaarsma, Tiny; Januzzi, James L; Jhund, Pardeep; Lopatin, Yuri; Lund, Lars H.; Metra, Marco; Milicic, Davor; Moura, Brenda; Mueller, Christian; Mullens, Wilfried; Núñez, Julio; Piepoli, Massimo F; Rakisheva, Amina; Ristić, Arsen D.; Rossignol, Patrick; Savarese, Gianluigi; Tocchetti, Carlo G.; van Linthout, Sophie; Volterrani, Maurizio; Seferovic, Petar; Rosano, Giuseppe; Coats, Andrew J. S.; Emdin, Michele; Bayes-Genis, Antoni.
I: European Journal of Heart Failure, Bind 24, Nr. 6, 2022, s. 944-958.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings
T2 - A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
AU - Aimo, Alberto
AU - Vergaro, Giuseppe
AU - González, Arantxa
AU - Barison, Andrea
AU - Lupón, Josep
AU - Delgado, Victoria
AU - Richards, A Mark
AU - de Boer, Rudolf A
AU - Thum, Thomas
AU - Arfsten, Henrike
AU - Hülsmann, Martin
AU - Falcao-Pires, Inês
AU - Díez, Javier
AU - Foo, Roger S. Y.
AU - Chan, Mark Yan Yee
AU - Anene-Nzelu, Chukwuemeka G.
AU - Abdelhamid, Magdy
AU - Adamopoulos, Stamatis
AU - Anker, Stefan D
AU - Belenkov, Yuri
AU - Ben Gal, Tuvia
AU - Cohen-Solal, Alain
AU - Böhm, Michael
AU - Chioncel, Ovidiu
AU - Jankowska, Ewa A.
AU - Gustafsson, Finn
AU - Hill, Loreena
AU - Jaarsma, Tiny
AU - Januzzi, James L
AU - Jhund, Pardeep
AU - Lopatin, Yuri
AU - Lund, Lars H.
AU - Metra, Marco
AU - Milicic, Davor
AU - Moura, Brenda
AU - Mueller, Christian
AU - Mullens, Wilfried
AU - Núñez, Julio
AU - Piepoli, Massimo F
AU - Rakisheva, Amina
AU - Ristić, Arsen D.
AU - Rossignol, Patrick
AU - Savarese, Gianluigi
AU - Tocchetti, Carlo G.
AU - van Linthout, Sophie
AU - Volterrani, Maurizio
AU - Seferovic, Petar
AU - Rosano, Giuseppe
AU - Coats, Andrew J. S.
AU - Emdin, Michele
AU - Bayes-Genis, Antoni
N1 - Publisher Copyright: © 2022 European Society of Cardiology.
PY - 2022
Y1 - 2022
N2 - In patients with heart failure, the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with heart failure with reduced ejection fraction because most studies on cardiac remodelling focused on this setting.
AB - In patients with heart failure, the beneficial effects of drug and device therapies counteract to some extent ongoing cardiac damage. According to the net balance between these two factors, cardiac geometry and function may improve (reverse remodelling, RR) and even completely normalize (remission), or vice versa progressively deteriorate (adverse remodelling, AR). RR or remission predict a better prognosis, while AR has been associated with worsening clinical status and outcomes. The remodelling process ultimately involves all cardiac chambers, but has been traditionally evaluated in terms of left ventricular volumes and ejection fraction. This is the second part of a review paper by the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology dedicated to ventricular remodelling. This document examines the proposed criteria to diagnose RR and AR, their prevalence and prognostic value, and the variables predicting remodelling in patients managed according to current guidelines. Much attention will be devoted to RR in patients with heart failure with reduced ejection fraction because most studies on cardiac remodelling focused on this setting.
KW - Biomarkers
KW - Ejection fraction
KW - Heart failure
KW - Imaging
KW - Predictors
KW - Remodelling
KW - Therapies
U2 - 10.1002/ejhf.2522
DO - 10.1002/ejhf.2522
M3 - Review
C2 - 35488811
AN - SCOPUS:85132639497
VL - 24
SP - 944
EP - 958
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1567-4215
IS - 6
ER -
ID: 328546921